Viking Therapeutics (VKTX) stock ripped higher on Sept. 22 after the biotech firm disclosed positive top-line results from its Phase 2 trial involving its lead dual GLP-1/GIP agonist — VK2735. The study showed up to 22% placebo-adjusted weight loss at 33 weeks and confirmed the viability of flexible monthly and biweekly dosing.
Following today’s surge, Viking Therapeutics stock is up roughly 8% versus the start of this year, but down the same from its July high.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
www.barchart.comWhat the Phase 2 Data Means for Viking Therapeutics Stock
The newly released data from the VK2735-102 maintenance study marks a significant de-risking milestone for Viking Therapeutics shares.
In the Phase 2 trial, participants transitioned to less frequent maintenance scheduled after an initial 21-week induction period where they lost up to 19% of their body weight.
According to VKTX, its candidate maintained up to 97% of weight loss with every-other-week administration and up to 90% with monthly dosing, offering an attractive, flexible treatment cadence for long-term adherence.
Plus, the biotech firm highlighted a clean safety and tolerability profile as well, which strengthens its competitive posture against existing winners (Zepbound and Wegovy) of the rapidly expanding obesity market.
Is It Worth Buying VKTX Shares Into Strength Today?
While today’s rally reflects newfound confidence in Viking's clinical pipeline, prospective investors must weigh both the potential upside and ongoing commercial risks.
On the plus side, VK2735 continues to demonstrate best-in-class efficacy and a favorable safety profile, positioning the company as a prime partner or acquisition target in the multi-billion-dollar weight-loss market.
However, buying into today’s strength carries tactical risks. Viking remains a clinical-stage biotech without commercialized product revenue, facing long-term capital requirements for Phase 3 trials and intense competition from established pharma giants.
Therefore, dollar cost averaging or waiting for a pullback may offer a safer entry into VKTX shares for risk-tolerant, long-term investors.
Wall Street Remains Bullish on Viking Therapeutics
It's also worth mentioning that Wall Street analysts remain bullish as ever on VKTX stock for the longer term.
The consensus rating on Viking Therapeutics remains at “Strong Buy,” with the mean price target of about $110 indicating potential for a nearly 200% rally from here.
www.barchart.com On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
SHOP Stock Jumps as Meta Expands Shopify Partnership Nebius Stock Spikes 4% on Higher Computer Prices. How to Play NBIS Stock Here. CRCL Stock Alert: What to Know as Circle Lands $100 Billion Deal With Binance VKTX Stock Soars as Viking Therapeutics Announces Positive GLP-1 Trial Results